Common Criticisms and Rebuttals of The BEST-CLI Trial

Peripheral artery disease (PAD) affects more than 230 million patients world-wide1 and its prevalence is increasing due to the aging world population and the epidemic of diabetes and metabolic syndrome. 2 Approximately 11% of those with PAD progress to chronic limb threatening ischemia (CLTI), the most severe form of chronic PAD3 that presents with non-healing wounds or ischemic rest pain4. Without revascularization, the rate of limb loss among those with CLTI is approximately 22% per year.5 In addition, patients with CLTI have a 2-year mortality rate as high as 40% and the risk of death is nearly 3-fold among those with major tissue loss.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Source Type: research